EMA PRAC Evaluates Safety of Gilead's Yescarta and Valneva's Ixchiq, Recommends Updates to Product Labels
Background and Significance of the Safety Review
From May 4th to 7th, 2026, the European Medicines Agency (EMA)'s Pharmacovigilance Risk Assessment Committee (PRAC) held its regular meeting to evaluate Periodic Safety Update Reports (PSURs) and safety signals for key marketed drugs. During this meeting, the safety risks associated with Gilead Sciences' blockbuster CAR-T therapy, Yescarta, and Valneva's first-in-class chikungunya vaccine, Ixchiq, were the main topics of discussion. The PRAC's proactive management ensures patient safety while also directly impacting the commercial value of pharmaceutical companies by enforcing strict product label changes.
Warning for Cerebral Edema Risk in Yescarta
Gilead's CD19-targeted CAR-T therapy, Yescarta, has been recommended to include a warning in its label regarding the risk of potentially fatal cerebral edema, a side effect that can occur in certain lymphoma patient populations. Based on the results of the previous meeting, the PRAC has refined the Risk Management Plan (RMP) for further product information updates. Yescarta is Gilead's leading cell therapy, and in 2025, sales in this sector decreased by 7% year-on-year to $1.8 billion (USD). This regulatory tightening could pose a significant burden on its market position.
Neurological Side Effects of Ixchiq and Impact on Sales
Valneva's live-attenuated vaccine, Ixchiq, is undergoing continuous monitoring due to reports of serious neurological risks, including aseptic meningitis and fatal encephalitis, that can occur after vaccination. In August 2025, the U.S. Food and Drug Administration (FDA) suspended its license due to safety concerns, leading to a voluntary withdrawal from the U.S. market. This EMA PRAC evaluation is a crucial test for maintaining its presence in the European market. Due to the absence of U.S. sales, Valneva's 2025 sales decreased by 3.3% year-on-year to 157.9 million euros (EUR), and its 2026 guidance has been lowered to a maximum of 150 million euros.
Interaction Between the Pharmaceutical Industry and Regulatory Authorities
The PRAC's safety evaluations impose risks on pharmaceutical companies, including increased regulatory compliance costs and a decline in product reputation. Even for marketed drugs, if adverse events are identified through real-time reporting and post-marketing surveillance (PASS), labels may be immediately revised or the product may be withdrawn from the market. In the case of CAR-T therapies, if safety issues arise, there may be a rapid shift in prescriptions to competing drugs such as Bristol Myers Squibb (BMS)'s Breyanzi or Novartis' Kymriah.
Introduction and Prospects of Digital Pharmacovigilance
The PRAC plans to utilize digital health technologies and real-time data analysis infrastructure to detect safety signals more quickly and accurately in the future. If a real-time adverse event tracking system is successfully implemented, it will be possible to actively prevent patient harm, but pharmaceutical companies will face increased risk management costs in the long term. As a result, it is expected that securing an independent safety monitoring system that can be quickly integrated with the regulatory authorities' advanced pharmacovigilance system will become a key competitive advantage for future biopharmaceutical companies.
The strengthening of European safety regulations for marketed cell therapies, Yescarta and Ixchiq, leads to decreased product reliability and prescription avoidance, directly impacting the short-term sales of Gilead and Valneva. In the case of Yescarta, the addition of a cerebral edema warning label, given its $1.8 billion in annual cell therapy sales in 2025, could accelerate the loss of market share to competitors such as BMS's Breyanzi. Valneva, which has already withdrawn from the U.S. market and has its 2026 sales guidance adjusted to a maximum of 150 million euros, faces a triple whammy in the European market as the issue of aseptic meningitis is highlighted, leading to a decline in trust in its overall pipeline and increased regulatory compliance costs. As regulatory authorities enhance real-time monitoring systems based on digital health, clinical and post-market risk management standards and cost burdens across the bio industry are expected to increase further.